You are here: Industry Insights > Sanofi

News List

Sanofi, Translate Bio ink mRNA vaccine R&D deal worth up to $805M fiercevaccines
June 26, 2018
Moving to expand its vaccine pipeline after some slip-ups last year, Sanofi is betting on Translate Bio's mRNA platform in up to five undisclosed infectious disease targets.
Recipharm Acquires Sanofi’s UK CMO Biz contractpharma
June 19, 2018
Recipharm has acquired Sanofi’s manufacturing center and business in Holmes Chapel, UK, expanding its inhalation capabilities in the growing respiratory drug market with commercial drug product manufacturing.
Recipharm to buy Sanofi inhalation contract business and plant in U.K. for $60M fiercepharma
June 14, 2018
Recipharm has struck a deal with Sanofi to buy the French drugmaker’s contract inhalation drug business and plant in the U.K., picking up new capabilities and clients in the process.
Want to score on social, pharma? Follow Sanofi's lead, experts say fiercepharma
June 05, 2018
Sanofi could have just let it go. When actress Roseanne Barr blamed its sleep aid Ambien for a racist post, the pharma company could have simply ignored it and let the Twitterverse call out the inaccuracy.
Sanofi extends master services agreement with Beactica pharmaceutical-technology
June 01, 2018
Sanofi has extended its master services agreement with Swedish drug discovery firm Beactica to characterise the interactions between new therapeutics and their target proteins.
Sanofi and Ablynx announce the successful results of the initial tender offer period worldpharmanews
May 23, 2018
Sanofi (Euronext: SAN; NYSE: SNY) and Ablynx (Euronext Brussels and Nasdaq: ABLX) today announced the results of the initial tender offer period of Sanofi's previously announced tender offers to acquire all of the outstanding shares
Regeneron, Sanofi's drug shows positive effect in lung cancer study biospectrumasia
May 21, 2018
Regeneron's U.S. marketing application seeking approval for cemiplimab, a PD-1 inhibitor, for cutaneous squamous cell carcinoma is currently under FDA review with an action date of October 28.
US priority review for Sanofi, Regeneron’s cemiplimab pharmatimes
May 03, 2018
US regulators are undertaking a priority review of Sanofi and Regeneron’s cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC)...
Sanofi: First-quarter 2018 Business EPS up 1.4% at CER biospace
April 28, 2018
Q1 2018 Change Change at CER IFRS net sales reported EUR7,898m -8.7% -0.4% IFRS net income reported EUR1,016m -82.2%(2) - IFRS EPS reported EUR0.81 -82.0%(2)
Sanofi Quarterly Sales Sluggish with Focus on Integrating Bioverativ and Ablynx biospace
April 28, 2018
Paris-based Sanofi reported mixed first-quarter revenues, with net sales down 8.7 percent to 7,898 million euros.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 43 44 Next page